Clinical efficacy, drug retention and recurrence of ixekizumab across psoriasis severities: a multicenter retrospective analysis of 354 patients
Clinical Summary
View sourceWhat was studied
Retrospective, multicenter real‑world analysis of 354 Chinese patients with plaque psoriasis (mild–moderate PASI <10 vs severe PASI ≥10) treated with ixekizumab, assessing PASI75/90/100, absolute PASI at 2, 4, 12, 24, and 52 weeks, plus 3‑year drug retention and recurrence.
Key findings
Baseline PASI averaged 5.6±2.6 in the mild–moderate group and 20±11 in the severe group; the mild–moderate group achieved higher PASI75/90 at most time points and consistently higher PASI100 rates versus the severe group. Groups were otherwise similar in age, disease duration, and comorbidities, except for a difference in male proportion.
Study limitations
Retrospective design using a single-country database may limit causal inference and generalizability. Sex distribution differed between severity groups, introducing potential confounding. Numeric response rates, drug retention, and recurrence results were not reported in the provided text.
Clinical implications
Expect stronger PASI responses to ixekizumab in milder plaque psoriasis than in severe disease; set patient expectations accordingly and consider earlier biologic use when appropriate.
Related Questions
Explore related topics and deepen your understanding